These health startups raised $124M in venture capital funding this week
Although the Covid-19 pandemic has continued its relentless spread across the globe, several startup companies have closed venture capital funding rounds this week.
Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Vor Biopharma raises $42M in Series A round to advance AML cell therapy toward clinic
5AM Ventures and RA Capital Management led the round. The company is developing hematopoietic stem cells engineered to be protected from targeted immunotherapies.
AI-powered risk prediction platform KenSci secures $22M
Polaris Partners led the Series B round, and Ignition Partners, Osage University Partners, Mindset Ventures and UL Ventures also participated.
Startup developing semi-synthetic protein therapies raises $63M to tame IL-2
Interleukin-2 has been plagued by low responses and scary side effects but Synthorx is adding synthetic amino acids and a polymer to the treatment in an effort to make it a more effective cancer therapy
New venture fund: About half Osage University Partners’ $215M pot will finance life sciences startups
About half of the new, $215 million fund from Osage University Partners will go towards life sciences startups. The Philadelphia-area venture firm only invests in tech transfer spinouts.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.